Leukaemia Section
Short Communication

del(5q) in acute lymphoblastic leukemia (ALL)
Adriana Zamecnikova, Soad al Bahar
annaadria@yahoo.com (AZ); Kuwait Cancer Control Center, Kuwait (SaB)

Published in Atlas Database: August 2019

Online updated version: http://AtlasGeneticsOncology.org/Anomalies/del5qALLID1768.html
Printable original version: http://documents.irevues.inist.fr/bitstream/handle/2042/70750/08-2019-del5qALLID1768.pdf
DOI: 10.4267/2042/70750

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Myelodysplastic syndrome (MDS) with an isolated 5q deletion (5q-syndrome), that may arise de novo or may be therapy-related is recognized as a distinct entity by the WHO classification. While del(5q) thought to contribute to the pathogenesis of myeloid neoplasms, it has also been reported in lymphoblastic leukemia, suggesting a common underlying mechanism.

Keywords
Myelodysplastic syndrome; acute lymphoblastic leukemia; lenalidomide; 5q- syndrome; tumor suppressor genes.

Identity
See Figure 1.

Clinics and pathology

Disease
Acute lymphoblastic leukemia

Etiology
Acute leukemia evolving from an underlying MDS with del(5q) is almost always of myeloid lineage and only anecdotal case reports of MDS transforming to ALL have been reported (Agostino et al., 2011; Jain et al., 2016). Whether the presence of del(5q) in these cases reflects the underlying myelodysplastic state that later evolved into ALL remains unclear. del(5q) in ALL is mostly associated with multiple cytogenetic abnormalities that thought to be due to clonal expansion from an abnormal pluripotent stem cell.

Figure 1. (A). Fluorescence in situ hybridization with Vysis LSI CSF1R (5q33-34)/5p15.2 probe (Abott Molecular/Vysis, US) showing 2 red and 2 green signals on a normal metaphase and only 1 red signal on a metaphase with 5q deletion. Inset: Partial karyotype with 5q deletion and with chromosome 5 in ’action’ (chromosome 5 breaks).
**Epidemiology**

At least 160 reported patients aged 0 to 86 years (98 males, 61 females, 1 unknown); prevalence of pediatric patients (86 patients) and there were 46 adults.

**B-cell acute lymphoblastic leukemia:** 70 patients aged 0 to 86 years (41 males and 28 females, 1 unknown); among them there were 22 adults (14 males and 8 females, aged 22 to 86 years; median 42 years) and 39 pediatric patients (22 males and 17 females, aged 0 to 18; median 6 years). In addition, there were 9 patients with unknown age (5 males and 3 females, 1 unknown).

**T-cell acute lymphoblastic leukemia:** 58 patients (35 males and 23 females aged 1 to 79 years); among them there were 17 adults (9 males and 8 females aged 19 to 79 years), 35 pediatric patients (22 males 13 females aged 1 to 18 years) and 6 patients with unknown age (4 males and 2 females).

32 patients had unspecified ALL (22 males, 10 females aged 3 to 81 years; median 13 years); 7 patients were adults (5 males and 2 females) aged 34 to 81 years (median 72 years), 12 were pediatric patients (8 males and 4 females aged 3 to 16 years; median 6 years) and there were 12 patients with unknown age (8 males and 4 females).

**Clinics**

In contrast to its presence in myeloid malignancies, isolated del(5q) is rare in ALL, thus its clinical significance is unknown. del(5q) also appears to be clinically insignificant in patients following cytotoxic therapy or tyrosine kinase inhibitor (TKI) therapy, similar to other clonal cytogenetic abnormalities if detected as a minor clone (Tang et al., 2015). del(5q) in ALL mainly found as a clonal evolution event associated with disease progression.

**Genetics**

Del(5q) may be found as sole abnormality at first, as an evolutionary event in other cases, and as a transient event in patients after being treated with cytotoxic agents or TKI for the prior malignancies.

**Cytogenetics**

**Cytogenetics morphological**

Excluded are patients with EBF1/PDGFRB fusion that arose from interstitial deletion of 5q33, occurring within the Philadelphia-like ALL subtype.

Del(5q) as a sole clonal cytogenetic abnormality was found in 11 patients (3 with B-ALL, 4 with T-ALL and 4 with unspecified ALL) (Kowalczyk et al., 1985; Brusamolino et al., 1988; Raimondi et al., 1988; Loncarevic et al., 1999; Midmer et al., 1999; Gmidene et al., 2008; Palau et al., 1991; Valtut et al., 1991; Theodossiou et al., 1992; Goud et al., 2015).

Among these patients, there was and a 5-year-old boy who had previously received chemotherapy for ALL that had been diagnosed nine months before (Palau et al., 1991), a 13-year-old boy in whom the rearrangement was transiently present 7 months following the diagnosis of Ph-positive ALL (Theodossiou et al., 1992).

**Del(5q) with other abnormalities**

Found in a sideline with del(20q) and +Y in 2 MDS patients transforming to B-ALL while on lenalidomide (Agostino et al., 2011) and with limited additional anomalies such as i(7)(q10) in 1 (Kaneko et al., 1989), +22 in 1 (Karst et al., 2006), der(19)t(1;19)(q23;p13) in 1 (Chen et al., 1992) and 1 had a clone with a Ph chromosome and del(5q) at diagnosis (Takechi et al., 1990). The t(12;21)(p13;q22) was present as a sole additional anomaly in 3 patients with B-cell ALL (Lu et al., 2002; South et al., 2006; Zhou et al., 2012) and in 8 it was part of a complex karyotype (Alvarez et al., 2005; Kuchinskaya et al., 2005; Jarosova et al., 2003; Martinou et al., 2005; Olsson et al., 2018), however it is possible that some additional pediatric patients had a cryptic t(12;21). 3 patients had dic(9;20) (Heerema et al., 1996; Strefford et al., 2007; An et al., 2008), t(9;22) (q34;q11) (Sessarego et al., 1991; Tsuchiya et al., 1995; Rieder et al., 1996; Lee et al., 2002; Onciu et al., 2002; Wetzler et al., 2004; Russell et al., 2008; De Braekeleer et al., 2010; Lundin et al., 2014; Olsson et al., 2018) in complex karyotypes. The majority of patients with T-ALL had karyotypes with combination of chromosome deletions and specific translocations such as t(4;11)(q21;p15) (Hussey et al., 1999), t(5;14)/HOX11L2 (Berger et al., 2003; Bernard et al., 2001), t(4;11)(q23;p15) (Zhang et al., 2012), t(7;10)(q34;q24) (Lai et al., 2000), t(7;11)(q35;p13) (Kaneko et al. ID: >1998), t(10;11)(p12;q21) (Matlawska-Wasowska et al., 2016), t(10;14)(q24;q11) (Grossmann et al., 2013) and inv(7)(p15q34) (Rowley et al., 1999; La Starza et al., 2016).

**Genes involved and proteins**

Deletions of 5q are heterozygous, and deleted regions can affect different genes that are involved in the regulation of hematopoiesis.

**Result of the chromosomal anomaly**

**Fusion protein**

Oncogenesis

Interstitial or terminal del(5q) as a sole clonal cytogenetic abnormality if detected as a minor clone (Tang et al., 2015). del(5q) clone (Tang et al., 2015).

**Excluded are patients with EBF1/PDGFRB fusion** that arose from interstitial deletion of 5q33, occurring within the Philadelphia-like ALL subtype. del(5q) as a sole clonal cytogenetic abnormality was found in 11 patients (3 with B-ALL, 4 with T-ALL and 4 with unspecified ALL) (Kowalczyk et al., 1985; Brusamolino et al., 1988; Raimondi et al., 1988; Loncarevic et al., 1999; Midmer et al., 1999; Gmidene et al., 2008; Palau et al., 1991; Valtut et al., 1991; Theodossiou et al., 1992; Goud et al., 2015).
chromosome 5 are common findings in MDS or acute myeloid leukemia (AML), but they may also occur in patients with ALL. Deletions of genetic material from 5q result in loss of tumor suppressor genes that may potentially play a role in the pathogenesis of these diseases. The long arm of chromosome 5 contains many genes that are relevant in hematopoiesis and several candidate genes including transcription factors, cytokines and their receptors, signal mediators and cell cycle regulators have been identified. These include the RPS14 gene on 5q33.1, a critical gene for the erythroid phenotype, a microRNA cluster on 5q32-33 important for the megakaryocytic phenotype, the EGR1 gene on 5q31 that plays a role in hematopoietic stem cell proliferation. Other genes such as NPM1 and APC, the transcription factor Egr1/Krox20, the cytoskeletal remodeling protein, alpha-catenin may also contribute to the disease phenotype and progression (Tang et al., 2015). Although a critical tumor suppressor gene has not yet been identified in ALL, several putative tumor suppressors such as NR3C1 and TCF7, located within the 5q31 common deleted region and TRIM41, ZFP62, MAPK9, MGAT1, and CNOT6, mapping at 5q35 have been found to be down-regulated in T- ALL (La Starza et al., 2016). Given the large size and variable pattern of 5q deletions, it is probable that the loss of several genes that act alone or in combination contribute to pathogenesis. The absence of a clear critical gene suggests that deletion of variable combinations of genes may result in a clinical spectrum ranging from myeloid malignancies to lymphoid leukemia.

References

Agostino NM, Ahmed B, Popescu D, Gheith S. Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature. Int J Clin Exp Pathol. 2011 Mar;4(3):322-6

Alvarez Y, Coll MD, Ortega JJ, Bastida P, Dastugue N, Guitart M, Caballín MR. Genetic abnormalities associated with the t(12;21) and their impact in the outcome of 56 patients with B-cell acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2011 Mar;4(3):322-6

An Q, Wright SL, Korriz JD, Matheson E, Minto L, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Hall AG, Harrison CJ, Irving JA, Strefford JC. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17050-4

Berger R, Dastugue N, Busson M, Van Den Akker J, Périot C, Balleteri P, Hagemeijer A, Michaux L, Charrin C, Pages MP, Mugneret F, Andréux J, Talpant M, Hélias C, Mauveaux L, Lafage-Pochitaloff M, Mazziconacci MJ, Cornillet-Lefebvre P, Radford I, Asnali V, Bilhou-Nabera C, Nguyen Khac F, Léonard C, Speleman F, Poppe B, Bastard C, Taviaux S, Quillichini B, Herens C, Grégoire MJ, Cavé H, Bernard OA. t(5;14)(HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogénétique HématoLOGique (GFCH). Leukemia. 2003 Sep;17(9):1851-7

Bernard OA, Busson-LeConiat M, Ballerini P, Mauchaffué M, Della Valle V, Monni R, Nguyen Khac F, Mercier T, Penard-Lacronique V, Pasturaud P, Gressin L, Heilig R, Daniel MT, Lessard M, Berger R. A new recurrent and specific cryptic translocation, t(5;14)(q55;p32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001 Oct;15(10):1495-504

Brusamolino E, Orlandi E, Morra E, Bernasconi P, Pagnucco G, Colombro A, Lazzarino M, Bernasconi C. Hematologic and clinical features of patients with chromosome 5 monosomy or deletion (5q) Med Pediatr Oncol 1988;16(2):88-94

Chen Z, Morgan R, Sandberg AA. Non-random involvement of chromosome 5 in ALL Cancer Genet Cytogenet 1992 Jul 1;61(1):106-7

De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinho A, Berthou C, Morice P, Férec C, De Braekeleer M. Philadelphia chromosome-positive acute lymphoblastic leukemia: a cytogenetic study of 33 patients diagnosed between 1981 and 2008 Anticancer Res 2010 Feb;30(2):569-73

Fader S, Gidel C, Kantarjian HM, Manshour T, Keating M, Albiser M. Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia Leuk Res 2001 Jan;25(1):39-43

Gniméde A, Sennama H, Elhezal H, Zirraou S, Youssel YB, Eloumi M, Issaoui L, Harrabi I, Raynoud S, Saad A. Cytogenetic analysis of 238 newly diagnosed cases of acute lymphoblastic leukaemia in Tunisia Hematol Oncol 2008 Jun;26(2):91-7

Goud TM, Al Salmani KK, Al Harasi SM, Al Musalhi A, Wasiufuddin SM, Rajab A. Importance of FISH combined with Morphology, Immunophenotype and Cytogenetic Analysis of Childhood/ Adult Acute Lymphoblastic Leukemia in Omani Patients Asian Pac J Cancer Prev 2015;16(10):7243-50

Grossmann V, Haferlach T, Weissmann S, Roller A, Schindela S, Poetzinger F, Stadler K, Bellos F, Kern W, Haferlach T, Schnittger S, Kohlmann A. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL Genes Chromosomes Cancer 2013 Apr;52(4):410-22

Heerema NA, Sather HN, Sensel MG, Kraft P, Nacnhan JB, Steinherz PG, Lange BJ, Hutchinson RS, Reaman GH, Trigg ME, Arthur DC, Gaynon PS, Uckun FM. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group J Clin Oncol 1998 Apr;16(4):1270-8

Hussey DJ, Nicola M, Moore S, Peters GB, Dobrovic A. The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphoblastic leukemia Blood 1999 Sep 15;94(6):2072-9

Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daven N, Estrov Z. Synchronous del(5q) myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations Am J Hematol 2016 Mar;91(3):354-5

Jarsova M, Volejnikova J, Porizkova I, Holzerova M, Pospisilova D, Novak Z, Vrbkova J, Mihal V. Chromosomal aberrations in childhood acute lymphoblastic leukemia: 15-
del(5q) in acute lymphoblastic leukemia (ALL)

Zamecnikova A, al Bahar S

year single center experience Cancer Genet 2016 Jul-Aug;209(7-8):340-7

Kaneko Y, Frizzera G, Shikano T, Kobayashi H, Maseki N, Sakurai M. Chromosomal and immunophenotypic patterns in T cell acute lymphoblastic leukemia (T ALL) and lymphoblastic lymphoma (LBL). Leukemia 1989 Dec;3(12):886-92

Kaneko Y, Maseki N, Horma C, Sakurai M, Mizutani S, Takeda T, Shikano T, Fujimoto T, Yai K, Shimokawa T. Chromosome translocations involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma Blood 1988 Aug;72(2):534-8

Karst C, Gross M, Haase D, Wedding U, Höffken K, Liehr T, Mirkhchyan H. Novel cryptic chromosomal rearrangements detected in acute lymphoblastic leukemia detected by application of new multicolor fluorescent in situ hybridization approaches Int J Oncol 2006 Apr;28(4):851-7

Kowalczyk J, Sandberg AA. A possible subgroup of ALL with 9p- Cancer Genet Cytogenet 1993 Aug;9(4):383-5

Kuchinskaia E, Heyman M, Grändér D, Lindenhof M, Söderhäll S, Zartisky A, Nordgren A, Porwit A, Tsakmakis M, Zemel D. Philadelphia chromosome 9q deletion in Philadelphia chromosome positive acute lymphoblastic leukemia have similar gene expression profiles Eur J Haematol 2005 Jun;74(6):466-80

La Starza R, Barba G, Demeysier S, Pierini V, Di Giacomo D, Gianfelici V, Schwab C, Matteucci C, Vicente C, Cools J, Messina M, Crescenzi B, Chiarietti S, Foà R, Basso G, Harrison CJ, Meucci C, Defferrari R, Fugazza G, Comelli A, Salvidio A, Palau F, Prieto F, Badia L, Benet I, Beneyto M. Chromosomal and immunophenotypic patterns of leukaemic cells with deletions or mutations of IKZF1 Genes Chromosomes Cancer 2015 Aug;20(4):315-25

Olsson L, Albitar F, Castor A, Behrendtz M, Biloglav A, Paulsson K, Johansson B. Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations of IKZF1 Genes Chromosomes Cancer 2015 May;54(5):315-25

Olsson L, Lundin-Ström KB, Castor A, Behrendtz M, Biloglav A, Norén-Nyström U, Paulsson K, Johansson B. Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: A single center experience of 296 cases Genes Chromosomes Cancer 2018 Nov;57(11):604-607

Onciu M, Bueso-Ramos C, Medeiros LJ, Ball G, Smith T, Lai R. Acute lymphoblastic leukemia in elderly patients The Philadelphia chromosome may not be a significant adverse prognostic factor Am J Clin Pathol 2002 May;117(5):716-20

Palau F, Prieto F, Badia L, Beneyto M, Benet I. Chromosome 5 abnormalities in acute lymphoblastic leukemia Cancer Genet Cytogenet 1991 Apr;52(2):173-9

Raimondi SC, Behm FG, Roberson PK, Pui CH, Rivera GK, Murphy SB, Williams DL. Cytogenetics of childhood T-cell acute leukemia Blood 1988 Nov;72(5):1560-6

Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JW, Gökgubet N, Schwartz S, Thiel E, Lößler H, Bartram CR, Hoelzer D, Fritsch S, Fottbach J. Prognostic significance of additional chromosome abnormalities in adults with Philadelphia chromosome positive acute lymphoblastic leukemia Blood 1996 Dec;88(11):3919-28

Rowley JD, Roshmi S, Carlson K, Roulston D. Spectral karyotyping analysis of T-cell acute leukemia Blood 1999 Mar;93(6):2038-42

Russell L, Akasaka T, Majid A, Sugimoto KJ, Loraine Karran E, Nagel I, Harder L, Glavice A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strehlfeld JC, Siebert R, Dyer MJ, Harrison CJ. I(6;14)(p22;q32): a new recurrent IG@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) Blood 2008 Jan 1,111(1):387-91

Sessarego M, Defferrari R, Fugazza G, Comelli A, Salvadino A, Ajmair F. Involvement of the short arm of the derivative chromosome 9 in Philadelphia-positive acute lymphoblastic leukemia Cancer Genet Cytogenet 1991 Mar;52(1):43-9

South ST, Frazer JK, Brothman AR, Chen Z. Unexpected cytogenetic finding in acute lymphoblastic leukemia: a case of del(5q) with a cryptic t(12;21) Cancer Genet Cytogenet 2006 Jul 15;168(2):177-8
del(5q) in acute lymphoblastic leukemia (ALL)

Zamecnikova A, al Bahar S

Strefford JC, Worley H, Barber K, Wright S, Stewart AR, Robinson HM, Betteney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, Moorman AV, Harrison CJ. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization Oncogene 2007 Jun 21;26(29):4306-18

Takechi M, Ohnishi A, Tanaka K, Kimura N, Kamada N. Acute T-lymphocytic leukemia with Ph1 and 5q-chromosome abnormalities and rearrangements of bcr and TCR-delta genes Leuk Res 1990;14(10):885-93

Tang G, Goswami RS, Liang CS, Bueso-Ramos CE, Hu S, DiNardo C, Medeiros LJ. Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant Am J Clin Pathol 2015 Jul;144(1):78-86

Theodossiou C, Scalise A, Troy K, Silverman L, Perdahl-Wallace E, Najfeld V. del(5q) in acute lymphoblastic leukemia with biphenotypic and early progenitor phenotype Cancer Genet Cytogenet 1992 Oct 15;63(2):89-94

Tsuchiya H, Migita M, Yamamori S, Kaneko Y, Adachi N, Nakamura T, Nobukuni Y, el-Sonbaty SS, Matsuda I. A late-appearing Philadelphia chromosome in acute lymphoblastic leukemia confirmed by expression of BCR-ABL mRNA Leukemia 1995 Oct;9(10):1689-93

Vattal C, Uettwiller F, Fiori E, Vattal B, Ruch JV, Oberling F. Mosaic 46,XY/92,XXYY,del(5)(q13 q34) in an adult lymphoblastic leukemia Leuk Res 1991;15(7):651-3

Wetzler M, Dodge RK, Mrózek K, Stewart CC, Carroll AJ, Tantravahi R, Vardiman JW, Larson RA, Bloomfield CD. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B Br J Haematol 2004 Feb;124(3):275-88

Zhang J, Ding L, Holmfeldt L, Wu G, Healley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato M, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Epperl K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Doeling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia Nature 2012 Jan 11;481(7380):157-63

Zhou MH, Gao L, Jing Y, Xu YY, Ding Y, Wang N, Wang W, Li MY, Han XP, Sun JZ, Wang LL, Yu L. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia Ann Hematol 2012 Aug;91(8):1235-43

This article should be referenced as such: Zamecnikova A, al Bahar S. del(5q) in acute lymphoblastic leukemia (ALL). Atlas Genet Cytogenet Oncol Haematol. 2020; 24(6):248-252.